| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemochromatosis | 17 | 2012 | 70 | 1.490 |
Why?
|
| Epilepsy | 5 | 2021 | 59 | 1.430 |
Why?
|
| Depression | 6 | 2021 | 383 | 1.220 |
Why?
|
| Female | 113 | 2020 | 18236 | 0.940 |
Why?
|
| Influenza, Human | 9 | 2016 | 122 | 0.930 |
Why?
|
| Iron Overload | 10 | 2012 | 37 | 0.910 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 7 | 2020 | 27 | 0.870 |
Why?
|
| Humans | 130 | 2022 | 29213 | 0.870 |
Why?
|
| Women's Health | 7 | 2020 | 226 | 0.790 |
Why?
|
| Histocompatibility Antigens Class I | 9 | 2010 | 58 | 0.780 |
Why?
|
| Adult | 59 | 2021 | 8466 | 0.750 |
Why?
|
| Pesticides | 6 | 2016 | 189 | 0.740 |
Why?
|
| Male | 94 | 2020 | 17872 | 0.740 |
Why?
|
| Infant, Very Low Birth Weight | 7 | 2017 | 47 | 0.740 |
Why?
|
| Iron | 10 | 2012 | 113 | 0.730 |
Why?
|
| Membrane Proteins | 10 | 2012 | 256 | 0.720 |
Why?
|
| Ferritins | 8 | 2010 | 46 | 0.710 |
Why?
|
| Diabetes Mellitus, Type 2 | 13 | 2019 | 1382 | 0.640 |
Why?
|
| Mutation | 10 | 2020 | 466 | 0.630 |
Why?
|
| Hispanic Americans | 10 | 2016 | 904 | 0.630 |
Why?
|
| Anxiety | 5 | 2021 | 159 | 0.580 |
Why?
|
| Cognition Disorders | 5 | 2019 | 390 | 0.570 |
Why?
|
| Genome-Wide Association Study | 10 | 2022 | 543 | 0.570 |
Why?
|
| Middle Aged | 48 | 2020 | 10868 | 0.560 |
Why?
|
| Occupational Exposure | 3 | 2016 | 224 | 0.560 |
Why?
|
| Dystonic Disorders | 5 | 2020 | 12 | 0.560 |
Why?
|
| North Carolina | 29 | 2016 | 1424 | 0.540 |
Why?
|
| Transients and Migrants | 2 | 2016 | 281 | 0.530 |
Why?
|
| Adolescent | 34 | 2018 | 3265 | 0.520 |
Why?
|
| Aged | 44 | 2020 | 9510 | 0.510 |
Why?
|
| African Americans | 15 | 2016 | 1373 | 0.510 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 5 | 2016 | 49 | 0.490 |
Why?
|
| Infant, Newborn | 17 | 2017 | 603 | 0.480 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.480 |
Why?
|
| Quality of Life | 8 | 2019 | 819 | 0.480 |
Why?
|
| Mass Screening | 5 | 2021 | 225 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2010 | 180 | 0.450 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.440 |
Why?
|
| Diabetes Mellitus | 9 | 2008 | 369 | 0.440 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2019 | 836 | 0.430 |
Why?
|
| Continental Population Groups | 6 | 2016 | 221 | 0.420 |
Why?
|
| Rural Population | 10 | 2010 | 248 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2017 | 148 | 0.400 |
Why?
|
| Dementia | 3 | 2019 | 234 | 0.400 |
Why?
|
| Cross-Sectional Studies | 15 | 2021 | 1365 | 0.390 |
Why?
|
| European Continental Ancestry Group | 14 | 2016 | 1131 | 0.390 |
Why?
|
| Psoriasis | 6 | 2005 | 334 | 0.390 |
Why?
|
| Glucocorticoids | 4 | 2003 | 149 | 0.380 |
Why?
|
| Dexamethasone | 2 | 2001 | 42 | 0.380 |
Why?
|
| Bronchopulmonary Dysplasia | 4 | 2002 | 10 | 0.380 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2016 | 88 | 0.370 |
Why?
|
| Prospective Studies | 10 | 2021 | 2027 | 0.370 |
Why?
|
| Risk Factors | 20 | 2020 | 3547 | 0.360 |
Why?
|
| Hospitalization | 6 | 2013 | 417 | 0.360 |
Why?
|
| Anxiety Disorders | 3 | 2021 | 61 | 0.340 |
Why?
|
| Genetic Testing | 6 | 2009 | 90 | 0.330 |
Why?
|
| Child, Preschool | 17 | 2018 | 1168 | 0.330 |
Why?
|
| Genotype | 18 | 2014 | 735 | 0.330 |
Why?
|
| Child | 21 | 2019 | 2221 | 0.320 |
Why?
|
| United States | 21 | 2020 | 3648 | 0.320 |
Why?
|
| Blood Pressure | 7 | 2022 | 807 | 0.320 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2020 | 182 | 0.310 |
Why?
|
| Asthma | 4 | 2003 | 397 | 0.310 |
Why?
|
| Laser Therapy | 3 | 2002 | 52 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2022 | 1079 | 0.290 |
Why?
|
| Phenotype | 12 | 2016 | 629 | 0.290 |
Why?
|
| Ethnic Groups | 8 | 2016 | 440 | 0.290 |
Why?
|
| Genetic Variation | 3 | 2019 | 251 | 0.290 |
Why?
|
| Genome, Human | 3 | 2019 | 129 | 0.290 |
Why?
|
| Influenza Vaccines | 3 | 2013 | 78 | 0.290 |
Why?
|
| Infant | 14 | 2016 | 973 | 0.290 |
Why?
|
| Self Care | 7 | 2016 | 137 | 0.280 |
Why?
|
| Agriculture | 6 | 2008 | 174 | 0.280 |
Why?
|
| Population Surveillance | 5 | 2015 | 119 | 0.280 |
Why?
|
| Transferrin | 6 | 2007 | 32 | 0.280 |
Why?
|
| Health Behavior | 4 | 2017 | 216 | 0.270 |
Why?
|
| Overweight | 2 | 2018 | 259 | 0.260 |
Why?
|
| Dietary Fats | 3 | 2009 | 108 | 0.260 |
Why?
|
| Environmental Exposure | 4 | 2008 | 87 | 0.260 |
Why?
|
| Aged, 80 and over | 17 | 2019 | 3726 | 0.260 |
Why?
|
| Disability Evaluation | 2 | 2016 | 211 | 0.250 |
Why?
|
| Survivors | 2 | 2016 | 145 | 0.250 |
Why?
|
| Mothers | 4 | 2014 | 81 | 0.250 |
Why?
|
| Premature Birth | 2 | 2015 | 39 | 0.250 |
Why?
|
| Indians, North American | 8 | 2010 | 108 | 0.240 |
Why?
|
| Age of Onset | 4 | 2019 | 95 | 0.240 |
Why?
|
| Diabetes Complications | 4 | 2010 | 171 | 0.240 |
Why?
|
| Prevalence | 11 | 2019 | 907 | 0.240 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 726 | 0.240 |
Why?
|
| Renin-Angiotensin System | 2 | 2016 | 182 | 0.240 |
Why?
|
| Geriatric Assessment | 2 | 2016 | 356 | 0.240 |
Why?
|
| Health Status | 6 | 2019 | 369 | 0.230 |
Why?
|
| Ultraviolet Therapy | 3 | 2002 | 39 | 0.230 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2021 | 93 | 0.220 |
Why?
|
| Hypertension | 3 | 2022 | 912 | 0.220 |
Why?
|
| Pre-Eclampsia | 2 | 2014 | 53 | 0.220 |
Why?
|
| Homozygote | 5 | 2010 | 57 | 0.220 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 240 | 0.210 |
Why?
|
| Young Adult | 10 | 2018 | 2413 | 0.210 |
Why?
|
| Obesity | 4 | 2018 | 1068 | 0.200 |
Why?
|
| Albuminuria | 3 | 2008 | 177 | 0.200 |
Why?
|
| Dystonia | 3 | 2019 | 12 | 0.200 |
Why?
|
| Smoking | 2 | 2017 | 439 | 0.200 |
Why?
|
| Blood Glucose | 3 | 2014 | 467 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2019 | 15 | 0.200 |
Why?
|
| Birth Weight | 4 | 2017 | 39 | 0.200 |
Why?
|
| Retinopathy of Prematurity | 1 | 2001 | 8 | 0.190 |
Why?
|
| Psychiatry | 1 | 2020 | 12 | 0.190 |
Why?
|
| Dysarthria | 1 | 2020 | 3 | 0.190 |
Why?
|
| Speech | 1 | 2020 | 8 | 0.190 |
Why?
|
| Dysphonia | 1 | 2020 | 8 | 0.190 |
Why?
|
| Prostaglandin D2 | 1 | 2000 | 4 | 0.190 |
Why?
|
| Housing | 3 | 2006 | 60 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2020 | 154 | 0.190 |
Why?
|
| Cohort Studies | 8 | 2018 | 1694 | 0.190 |
Why?
|
| Aging | 3 | 2016 | 881 | 0.190 |
Why?
|
| Vitamin A | 1 | 2000 | 19 | 0.190 |
Why?
|
| Transposition of Great Vessels | 1 | 2000 | 2 | 0.190 |
Why?
|
| Ventricular Dysfunction | 1 | 2000 | 4 | 0.190 |
Why?
|
| Dinoprostone | 1 | 2000 | 37 | 0.190 |
Why?
|
| Neoplasms | 2 | 2016 | 612 | 0.180 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 41 | 0.180 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 196 | 0.180 |
Why?
|
| Hemiplegia | 1 | 2019 | 12 | 0.180 |
Why?
|
| African Continental Ancestry Group | 6 | 2010 | 350 | 0.180 |
Why?
|
| Milk | 1 | 1999 | 11 | 0.180 |
Why?
|
| Lactation | 1 | 1999 | 14 | 0.180 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 15 | 0.180 |
Why?
|
| Pregnancy | 7 | 2016 | 816 | 0.180 |
Why?
|
| Agricultural Workers' Diseases | 2 | 2006 | 86 | 0.170 |
Why?
|
| Patient Participation | 1 | 2020 | 62 | 0.170 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 58 | 0.170 |
Why?
|
| Primary Health Care | 4 | 2005 | 181 | 0.170 |
Why?
|
| Body Weight | 2 | 2018 | 290 | 0.170 |
Why?
|
| Ataxia | 2 | 2016 | 6 | 0.170 |
Why?
|
| Uric Acid | 2 | 2017 | 24 | 0.170 |
Why?
|
| Logistic Models | 6 | 2019 | 729 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 86 | 0.170 |
Why?
|
| Exercise | 2 | 2019 | 595 | 0.170 |
Why?
|
| Parkinsonian Disorders | 2 | 2019 | 9 | 0.170 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 1017 | 0.160 |
Why?
|
| Cognition | 2 | 2019 | 526 | 0.160 |
Why?
|
| Fractures, Bone | 2 | 2020 | 150 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 466 | 0.160 |
Why?
|
| Rural Health | 3 | 2007 | 43 | 0.160 |
Why?
|
| Emergency Service, Hospital | 4 | 2016 | 431 | 0.160 |
Why?
|
| Incidence | 5 | 2020 | 1123 | 0.160 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 638 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 17 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2003 | 90 | 0.150 |
Why?
|
| Sex Factors | 5 | 2016 | 632 | 0.150 |
Why?
|
| Depressive Disorder | 2 | 2010 | 74 | 0.150 |
Why?
|
| Interviews as Topic | 8 | 2008 | 249 | 0.150 |
Why?
|
| Erythropoiesis | 1 | 2016 | 6 | 0.150 |
Why?
|
| Attitude to Health | 2 | 2017 | 148 | 0.150 |
Why?
|
| Dermatomyositis | 2 | 2007 | 19 | 0.150 |
Why?
|
| Erythrocytes | 1 | 2016 | 43 | 0.150 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 864 | 0.150 |
Why?
|
| Caffeine | 1 | 2016 | 31 | 0.140 |
Why?
|
| Genetic Loci | 3 | 2012 | 147 | 0.140 |
Why?
|
| Heart Rate | 2 | 2016 | 315 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 68 | 0.140 |
Why?
|
| Age Distribution | 2 | 2014 | 198 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2016 | 61 | 0.140 |
Why?
|
| Melanoma | 2 | 2001 | 148 | 0.140 |
Why?
|
| Polysomnography | 1 | 2016 | 33 | 0.140 |
Why?
|
| Pair Bond | 1 | 2015 | 2 | 0.140 |
Why?
|
| Animals, Laboratory | 1 | 2015 | 4 | 0.140 |
Why?
|
| Tennessee | 6 | 2013 | 97 | 0.140 |
Why?
|
| Housing, Animal | 1 | 2015 | 23 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 47 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 2 | 2012 | 22 | 0.130 |
Why?
|
| Immunization Programs | 2 | 2013 | 26 | 0.130 |
Why?
|
| Automobile Driving | 1 | 2015 | 24 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2016 | 860 | 0.130 |
Why?
|
| Sleep | 1 | 2016 | 87 | 0.130 |
Why?
|
| Health Surveys | 5 | 2016 | 191 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 312 | 0.130 |
Why?
|
| Clinical Medicine | 1 | 2015 | 13 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2015 | 24 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2001 | 206 | 0.130 |
Why?
|
| Child Welfare | 2 | 2006 | 19 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2017 | 133 | 0.130 |
Why?
|
| Infant, Premature | 4 | 2016 | 62 | 0.130 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2014 | 5 | 0.130 |
Why?
|
| HLA-B27 Antigen | 1 | 2014 | 7 | 0.130 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2014 | 9 | 0.130 |
Why?
|
| HMGA2 Protein | 1 | 2014 | 13 | 0.130 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3121 | 0.130 |
Why?
|
| Heart Failure | 1 | 2000 | 571 | 0.130 |
Why?
|
| Homeostasis | 1 | 2014 | 127 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2114 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 104 | 0.120 |
Why?
|
| Molecular Epidemiology | 2 | 2011 | 20 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 28 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2015 | 126 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2013 | 35 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 35 | 0.120 |
Why?
|
| Dermatitis, Occupational | 1 | 2003 | 10 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 327 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 29 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2003 | 18 | 0.120 |
Why?
|
| Women's Health Services | 1 | 2013 | 9 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2003 | 24 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2015 | 212 | 0.110 |
Why?
|
| Clobetasol | 1 | 2003 | 25 | 0.110 |
Why?
|
| Pyridines | 1 | 2003 | 78 | 0.110 |
Why?
|
| Zinc | 1 | 2003 | 32 | 0.110 |
Why?
|
| Dermatology | 2 | 2002 | 154 | 0.110 |
Why?
|
| Lipectomy | 1 | 2002 | 9 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2013 | 100 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2005 | 156 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2002 | 27 | 0.110 |
Why?
|
| Whooping Cough | 1 | 2012 | 10 | 0.110 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2012 | 7 | 0.110 |
Why?
|
| Liver Diseases | 3 | 2008 | 61 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2019 | 448 | 0.110 |
Why?
|
| Dermatologic Agents | 2 | 2002 | 208 | 0.110 |
Why?
|
| Platelet Count | 1 | 2012 | 21 | 0.110 |
Why?
|
| Mood Disorders | 1 | 2012 | 19 | 0.110 |
Why?
|
| Rotavirus Vaccines | 1 | 2012 | 7 | 0.110 |
Why?
|
| Rotavirus Infections | 1 | 2012 | 11 | 0.110 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2012 | 110 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2012 | 37 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 162 | 0.100 |
Why?
|
| Postmenopause | 3 | 2020 | 397 | 0.100 |
Why?
|
| Family | 2 | 2010 | 105 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2011 | 55 | 0.100 |
Why?
|
| Phototherapy | 1 | 2001 | 47 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2012 | 111 | 0.100 |
Why?
|
| Memory | 1 | 2013 | 187 | 0.100 |
Why?
|
| Body Mass Index | 6 | 2016 | 867 | 0.100 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2011 | 2 | 0.100 |
Why?
|
| Adiposity | 1 | 2012 | 192 | 0.100 |
Why?
|
| Time Factors | 5 | 2016 | 2003 | 0.100 |
Why?
|
| Lod Score | 4 | 2007 | 71 | 0.100 |
Why?
|
| Alcoholism | 1 | 2012 | 98 | 0.100 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2000 | 9 | 0.100 |
Why?
|
| Body Composition | 3 | 2017 | 365 | 0.100 |
Why?
|
| Creatinine | 2 | 2008 | 174 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 28 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 724 | 0.100 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 23 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2001 | 134 | 0.100 |
Why?
|
| Hemoglobin C | 1 | 2010 | 2 | 0.090 |
Why?
|
| Vaccination | 1 | 2011 | 123 | 0.090 |
Why?
|
| Oceanic Ancestry Group | 2 | 2007 | 7 | 0.090 |
Why?
|
| Sickle Cell Trait | 1 | 2010 | 12 | 0.090 |
Why?
|
| Pneumococcal Infections | 1 | 2010 | 30 | 0.090 |
Why?
|
| Family Health | 2 | 2007 | 78 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 223 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2010 | 48 | 0.090 |
Why?
|
| Age Factors | 5 | 2007 | 1110 | 0.090 |
Why?
|
| Arteries | 1 | 2010 | 60 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 65 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 394 | 0.090 |
Why?
|
| Chromosome Mapping | 3 | 2003 | 190 | 0.090 |
Why?
|
| Gene Frequency | 5 | 2007 | 225 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2000 | 97 | 0.090 |
Why?
|
| Diet, Fat-Restricted | 1 | 2009 | 30 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2000 | 285 | 0.090 |
Why?
|
| Antidepressive Agents | 2 | 2020 | 70 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2010 | 3108 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2001 | 307 | 0.080 |
Why?
|
| Prognosis | 3 | 2017 | 1363 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2008 | 32 | 0.080 |
Why?
|
| Apolipoproteins B | 1 | 2007 | 44 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2007 | 26 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2011 | 35 | 0.080 |
Why?
|
| Genetic Markers | 3 | 2001 | 122 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2008 | 274 | 0.080 |
Why?
|
| DNA | 1 | 2008 | 204 | 0.080 |
Why?
|
| RNA Splice Sites | 1 | 2007 | 1 | 0.080 |
Why?
|
| Gestational Age | 2 | 2002 | 96 | 0.080 |
Why?
|
| Religion and Psychology | 1 | 2007 | 7 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 157 | 0.070 |
Why?
|
| Cation Transport Proteins | 1 | 2007 | 24 | 0.070 |
Why?
|
| Ownership | 1 | 2007 | 14 | 0.070 |
Why?
|
| Equipment and Supplies | 1 | 2007 | 15 | 0.070 |
Why?
|
| Cholesterol | 2 | 2019 | 229 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2007 | 19 | 0.070 |
Why?
|
| Fetal Organ Maturity | 2 | 2016 | 7 | 0.070 |
Why?
|
| Movement Disorders | 2 | 2019 | 25 | 0.070 |
Why?
|
| Asian Americans | 1 | 2007 | 98 | 0.070 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 140 | 0.070 |
Why?
|
| California | 3 | 2012 | 60 | 0.070 |
Why?
|
| Heterozygote | 2 | 2019 | 52 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2005 | 252 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2003 | 504 | 0.070 |
Why?
|
| Medicaid | 2 | 2000 | 83 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2007 | 114 | 0.070 |
Why?
|
| Health Promotion | 1 | 2008 | 220 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2006 | 164 | 0.070 |
Why?
|
| Administration, Topical | 3 | 2003 | 130 | 0.070 |
Why?
|
| Complementary Therapies | 1 | 2006 | 75 | 0.070 |
Why?
|
| Energy Intake | 3 | 2000 | 120 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 39 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 379 | 0.060 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2005 | 24 | 0.060 |
Why?
|
| Specialization | 1 | 2005 | 30 | 0.060 |
Why?
|
| Diabetic Foot | 1 | 2005 | 19 | 0.060 |
Why?
|
| Health Services for the Aged | 1 | 2005 | 25 | 0.060 |
Why?
|
| Medicine | 1 | 2005 | 30 | 0.060 |
Why?
|
| Rural Health Services | 1 | 2005 | 27 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2016 | 192 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 60 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 709 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 26 | 0.060 |
Why?
|
| Accidental Falls | 1 | 2006 | 207 | 0.060 |
Why?
|
| Acute Disease | 2 | 2018 | 239 | 0.060 |
Why?
|
| Administration, Inhalation | 2 | 2000 | 92 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 118 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 533 | 0.060 |
Why?
|
| Medicare | 1 | 2005 | 187 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2013 | 13 | 0.060 |
Why?
|
| Seasons | 2 | 2013 | 84 | 0.060 |
Why?
|
| Communication | 1 | 2004 | 122 | 0.060 |
Why?
|
| Alleles | 2 | 2016 | 251 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 231 | 0.050 |
Why?
|
| Immunization Schedule | 2 | 2012 | 24 | 0.050 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 1992 | 3 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1992 | 7 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 1992 | 20 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2006 | 1312 | 0.050 |
Why?
|
| Lasers | 2 | 2002 | 19 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 401 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 82 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 2012 | 72 | 0.050 |
Why?
|
| Virginia | 3 | 2008 | 64 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2001 | 13 | 0.050 |
Why?
|
| Africa | 2 | 2016 | 23 | 0.050 |
Why?
|
| Animals | 3 | 2016 | 7302 | 0.050 |
Why?
|
| Demography | 2 | 2015 | 104 | 0.050 |
Why?
|
| Europe | 2 | 2016 | 77 | 0.050 |
Why?
|
| Research Design | 1 | 2003 | 286 | 0.050 |
Why?
|
| Lactates | 1 | 1990 | 2 | 0.050 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2000 | 4 | 0.050 |
Why?
|
| Retinol-Binding Proteins | 1 | 2000 | 3 | 0.050 |
Why?
|
| Parents | 2 | 2012 | 121 | 0.050 |
Why?
|
| Gallbladder Diseases | 1 | 2020 | 5 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 1990 | 21 | 0.050 |
Why?
|
| Allergens | 1 | 2000 | 16 | 0.050 |
Why?
|
| Patient Preference | 1 | 2020 | 38 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2000 | 17 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 39 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2000 | 95 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2000 | 67 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2000 | 56 | 0.050 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2020 | 89 | 0.050 |
Why?
|
| Data Collection | 2 | 2008 | 163 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2000 | 39 | 0.050 |
Why?
|
| Leptin | 1 | 2000 | 66 | 0.050 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2020 | 125 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2000 | 71 | 0.040 |
Why?
|
| Freezing | 1 | 1999 | 2 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 113 | 0.040 |
Why?
|
| Centrifugation | 1 | 1999 | 3 | 0.040 |
Why?
|
| Nutritive Value | 1 | 1999 | 7 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2016 | 454 | 0.040 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Recombinases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 34 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2019 | 28 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2000 | 139 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 36 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 72 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 97 | 0.040 |
Why?
|
| Lung | 1 | 2000 | 233 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1988 | 10 | 0.040 |
Why?
|
| Insulin | 1 | 1990 | 346 | 0.040 |
Why?
|
| Ascites | 1 | 1988 | 13 | 0.040 |
Why?
|
| Canada | 2 | 2008 | 49 | 0.040 |
Why?
|
| North America | 2 | 2009 | 33 | 0.040 |
Why?
|
| Lipids | 1 | 1999 | 211 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 1988 | 75 | 0.040 |
Why?
|
| Pedigree | 2 | 2012 | 133 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 29 | 0.040 |
Why?
|
| Far East | 1 | 2016 | 4 | 0.040 |
Why?
|
| Zebrafish | 1 | 2016 | 24 | 0.040 |
Why?
|
| Safety | 2 | 2008 | 73 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2016 | 68 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2008 | 186 | 0.040 |
Why?
|
| Arthritis | 2 | 2008 | 37 | 0.040 |
Why?
|
| Snoring | 1 | 2016 | 8 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 2016 | 42 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 232 | 0.040 |
Why?
|
| Life Change Events | 1 | 2016 | 21 | 0.040 |
Why?
|
| Cerebellum | 1 | 2016 | 29 | 0.040 |
Why?
|
| Twins | 1 | 1986 | 3 | 0.040 |
Why?
|
| Atrophy | 1 | 2016 | 51 | 0.040 |
Why?
|
| Linear Models | 1 | 2017 | 427 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 28 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2016 | 36 | 0.030 |
Why?
|
| Heart Diseases | 2 | 2008 | 99 | 0.030 |
Why?
|
| Body Height | 1 | 1986 | 31 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 71 | 0.030 |
Why?
|
| Renin | 1 | 2016 | 112 | 0.030 |
Why?
|
| Proxy | 1 | 2015 | 9 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2015 | 33 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2016 | 65 | 0.030 |
Why?
|
| Term Birth | 1 | 2015 | 3 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 481 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2016 | 131 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 267 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 88 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 2 | 2005 | 24 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 35 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 67 | 0.030 |
Why?
|
| Genome | 1 | 2014 | 40 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 22 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2016 | 279 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2014 | 20 | 0.030 |
Why?
|
| Angiotensin I | 1 | 2016 | 262 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 322 | 0.030 |
Why?
|
| Aldosterone | 1 | 2014 | 28 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2015 | 211 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 364 | 0.030 |
Why?
|
| Mexico | 1 | 2003 | 63 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 333 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 422 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 25 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2003 | 30 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 172 | 0.030 |
Why?
|
| New York | 1 | 2013 | 18 | 0.030 |
Why?
|
| Hyaline Membrane Disease | 1 | 2002 | 1 | 0.030 |
Why?
|
| Apgar Score | 1 | 2002 | 5 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2002 | 9 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 16 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 2002 | 7 | 0.030 |
Why?
|
| Solutions | 1 | 2002 | 26 | 0.030 |
Why?
|
| Surgicenters | 1 | 2002 | 3 | 0.030 |
Why?
|
| Physicians' Offices | 1 | 2002 | 9 | 0.030 |
Why?
|
| Ohio | 1 | 2013 | 55 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2002 | 11 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2007 | 94 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2012 | 12 | 0.030 |
Why?
|
| New York City | 1 | 2002 | 13 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2002 | 91 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 273 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2012 | 8 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2012 | 19 | 0.030 |
Why?
|
| Maryland | 1 | 2002 | 26 | 0.030 |
Why?
|
| Precipitating Factors | 1 | 2012 | 2 | 0.030 |
Why?
|
| Focus Groups | 1 | 2002 | 104 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 248 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2002 | 77 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2012 | 29 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2012 | 29 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2012 | 11 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2012 | 21 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2002 | 72 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2012 | 107 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2001 | 24 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2012 | 71 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 39 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2001 | 34 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2001 | 27 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2001 | 33 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 281 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 10 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2012 | 175 | 0.030 |
Why?
|
| Duffy Blood-Group System | 1 | 2011 | 4 | 0.030 |
Why?
|
| Chemokine CXCL2 | 1 | 2011 | 9 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 788 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2012 | 60 | 0.030 |
Why?
|
| DNA Replication | 1 | 2011 | 23 | 0.030 |
Why?
|
| Artifacts | 1 | 2011 | 38 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 33 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 6 | 0.030 |
Why?
|
| Recurrence | 1 | 2002 | 235 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2000 | 28 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1219 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2000 | 10 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 25 | 0.020 |
Why?
|
| Myocarditis | 1 | 2000 | 6 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 290 | 0.020 |
Why?
|
| Elasticity | 1 | 2010 | 34 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2010 | 40 | 0.020 |
Why?
|
| Arm | 1 | 2010 | 31 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 196 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 59 | 0.020 |
Why?
|
| Leg | 1 | 2010 | 56 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2010 | 66 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 246 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2008 | 9 | 0.020 |
Why?
|
| Nutritional Sciences | 1 | 2008 | 8 | 0.020 |
Why?
|
| Kentucky | 1 | 2007 | 15 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 23 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 375 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2007 | 40 | 0.020 |
Why?
|
| Hemosiderosis | 1 | 2007 | 2 | 0.020 |
Why?
|
| Protestantism | 1 | 2007 | 5 | 0.020 |
Why?
|
| Vietnam | 1 | 2007 | 23 | 0.020 |
Why?
|
| Point Mutation | 1 | 2007 | 23 | 0.020 |
Why?
|
| Health Education | 1 | 2008 | 121 | 0.020 |
Why?
|
| Laundering | 1 | 2006 | 4 | 0.020 |
Why?
|
| Baths | 1 | 2006 | 6 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 183 | 0.020 |
Why?
|
| Attitude | 1 | 2006 | 37 | 0.020 |
Why?
|
| Religion | 1 | 2006 | 30 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2006 | 32 | 0.020 |
Why?
|
| Dermatitis | 1 | 2005 | 20 | 0.020 |
Why?
|
| Comorbidity | 1 | 2007 | 546 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 126 | 0.020 |
Why?
|
| Confidentiality | 1 | 2005 | 22 | 0.020 |
Why?
|
| Social Support | 1 | 2007 | 164 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2006 | 91 | 0.020 |
Why?
|
| Pruritus | 1 | 2005 | 58 | 0.020 |
Why?
|
| American Native Continental Ancestry Group | 1 | 2005 | 13 | 0.020 |
Why?
|
| Geography | 1 | 2005 | 34 | 0.020 |
Why?
|
| Thrombosis | 1 | 2005 | 60 | 0.020 |
Why?
|
| Educational Status | 1 | 2005 | 165 | 0.020 |
Why?
|
| Poverty | 1 | 2005 | 99 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2004 | 22 | 0.020 |
Why?
|
| Language | 1 | 2004 | 44 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 13 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 177 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2003 | 7 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 39 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2001 | 9 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2001 | 11 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2001 | 15 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1992 | 105 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 257 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 350 | 0.010 |
Why?
|
| Theophylline | 1 | 2000 | 4 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1990 | 125 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1990 | 52 | 0.010 |
Why?
|
| Basal Metabolism | 1 | 2000 | 8 | 0.010 |
Why?
|
| Health Resources | 1 | 2000 | 33 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 50 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 169 | 0.010 |
Why?
|
| Fasting | 1 | 2000 | 93 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2000 | 111 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 82 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2000 | 167 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2000 | 370 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 21 | 0.010 |
Why?
|
| Diet | 1 | 2000 | 356 | 0.010 |
Why?
|